Frontlight ResearchEarly access
CompletedNo phase
Vascular Fingerprint Validation Study
Key facts
- Who runs it
- University Medical Center Groningen
- Where
- Netherlands, Portugal, and Switzerland5 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 101 people enrolled
- Started
- 1 Oct 2015
- Ended
- 1 Apr 2024
- Type of study
- Observational
- Record updated
- 17 May 2024
Who can take part
- Age
- 18 years to 50 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of metastatic TC and an indication to start with first-line cisplatin-based chemotherapy for metastatic TC
- Classified into IGCCCG good or intermediate prognosis group
- Younger than 50 years of age at start of chemotherapy
- Signed informed consent
Who cannot take part
- History of previous cardiovascular disease
- Indication for anticoagulant therapy at start of chemotherapy
- Retroperitoneal mass > 5 cm
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The vascular fingerprint is a simple selection tool to identify testicular cancer patients with a high risk of arterial cardiovascular events during and in the first year after cisplatin chemotherapy. Eventually, this selection method allows a relative small randomized intervention study with i.e. LMWH during chemotherapy to prove the effectiveness and safety in lowering the chance of an arterial cardiovascular event.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study
- Record updated
- 17 May 2024